natgillin/translations-raw huggingface dataset:
The sanding element according to the invention has the features of claim 1, and makes it possible to remove material from the workpiece as well as to perfectly finish the workpiece, both from an aesthetic and a technical point of view. 
Element za brušenje koji je u skladu s ovim izumom ima karakteristike koje su navedene u patentnom zahtjevu 1, i omogućava uklanjanje materijala s komada koji se obrađuje, kao i savršenu konačnu obradu komada koji se obrađuje, i to i sa estetskog gledišta i sa tehničkog gledišta.
An IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein 
Fc regija klase IgG koja sadrži polipeptid prve varijante Fc regije i polipeptid druge varijante Fc regije, naznačena time, da se
applying a protective powder based or paper based overlay (1) comprising a melamine formaldehyde resin and aluminum oxide on said raw paper (2); applying heat and pressure in order to impregnate the raw paper (2), to cure the resin and thereby obtain a laminated product. 
* nanošenje zaštitnog sloja prevlake na bazi praha ili na bazi papira (1) koji sadrži čestice od smole i čestice otporne na habanje na navedeni sirovi papir (2); i * primjenu topline i tlaka radi impregniranja sirovog papira (2) i stvrdnjavanja smola, čime se dobiva laminirani proizvod.
The resulting mixture is poured into water (30 ml) and extracted with 1:1 EtOAc/ether. 
Dobivenu smjesu se prelije u vodu (30 ml) i ekstrahira se s 1:1 FtOAc/eterom.
The use according to claim 8, wherein the interferon is interferon-B. 
Uporaba prema zahtjevu 8, naznačena time da interferon je interferon-f.
Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally. 
Pripravci za produljeno otpuštanje, poput onih obloženih polimerom, može se izravno primijeniti intracerebralno.
The composition for use according to claim 1, wherein the method of treating further comprises monitoring the subject for an adverse effect after the administration of the composition, wherein if an adverse effect is observed, the therapeutically effective amount of the composition is decreased. 
dC ili dT, namijenjeni upotrebi u skladu s patentnim zahtjevom 1 odnosno 2, naznačeni time što postupak liječenja dodatno uključuje praćenje subjekta na štetni učinak nakon primjene pripravka, gdje ako se opazi štetni učinak, terapijski djelotvornu količinu pripravka se smanjuje.
A compound of claim 1 or 2, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R<3> has the formula, 
Naši Sa Å BE iš ili stereoizomer, tautomer, farmaceutski-prihvatljivu sol, ili solvat tog spoja.
a second QAM mapper configured to demultiplex the interleaved PLP data into cell words and map the cell words into constellation values; and a time-frequency interleaver configured to time-frequency interleave the mapped constellation values. 
drugi dio za mapiranje QAM-a (306) podešen za demultipleksiranje umetnutih PLP podataka u stanične riječi i mapiranje staničnih riječi u konstelacijske vrijednosti; i dio za umetanje vremena-frekvencije (708-0, 709-0) podešen za umetanje vremena-frekvencije mapiranih konstelacijskih vrijednosti.
The apparatus of any one of claims 1 through 12, wherein the apparatus assesses the composition of the composite sample, the non-composite sample, and/or the sample of the additional fluid. 
Uređaj prema bilo kojem od zahtjeva 1 do 12, naznačen time da uređaj procjenjuje sastav kompozitnog uzorka, nekompozitnog uzorka, i/ili uzorka dodatnog fluida.
The monitoring device 33 operates purely mechanically in the embodiment illustrated. 
U prikazanoj izvedbi naprava za praćenje 33 djeluje čisto mehanički.
After this incubation period, orange formazan solution was formed, which was spectrophotometrically quantified using an ELISA plate reader at 450 nm 
Nakon tog perioda inkubacije, nastala je narančasta otopina formazana, čija količina je utvrđena spektrofotometrijski upotrebom čitača ELISA pločice pri 450 nm.
adding diethylene glycol monoethyl ether to rifaximin, in a molar ratio ranging from 10:1 to 100:1, at temperatures ranging from room temperature to 100°C for a duration of time ranging from 5 minutes to 5 hours to provide a rifaximin solution; 
– dodavanja dietilen-glikol-monoetil-etera rifaksiminu, u molarnom omjeru u rasponu od 10:1 do 100:1, na temperaturama u rasponu od sobne temperature do 100 °C u trajanju u rasponu od 5 minuta do 5 sati kako bi se dobilo otopinu rifaksimina;
In some embodiments, in conjunction with other above or below embodiments, Form A can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples, having peaks at about 6.6, 14.9, 20.1, 21.4, and 26.8±0.2° 2θ using Cu Ka radiation. 
4. Sol prema bilo kojem od zahtjeva 1 do 3, pri čemu je sol naznačena time što ima uzorak rendgenske difrakcije na prahu koji sadrži vrhove kod 6.6, 14.9, 20.1, 21.4, i 26.8 + 0.2* 20 korištenjem Cu Ka zračenja.
A monoclonal antibody that specifically binds to the AD1 region of human cytomegalovirus (HCMV) glycoprotein gB and that is capable of neutralizing the bioactivity thereof, wherein 
Protutijelo ili njegov fragment koji se veže na antigen, naznačen/o time, da se specifično veže na glikoprotein gB od humanog citomegalovirusa te koje/koji može neutralizirati njegovo biološko djelovanje, pri čemu
A process for the preparation of a compound of formula III as defined in Paragraph 5, which process comprises reaction of a compound of formula IV, 
Postupak za dobivanje spoja formule III kao što je definirano u zahtjevu 5, naznačen time da postupak sadrži reakciju spoja formule IV,
The composition according to claim 1, characterized in that the weight ratio of aforesaid three Extracts prepared by RadiX Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae alba, Radix Rehmanniae Preparata, Ramulus Uncariae cum Uncis, Caulis Spatholobi, Spica Prunellae, Semen Cassiae, Concha Margaritifera Usta, Rhizoma Corydalis and Herba Asari to the excipients is 40:60 to 65:35, preferably 55:45 to 65:35. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time, da je težinski omjer gore navedenih triju ekstrakata pripravljenih od Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae alba, Radix Rehmanniae Preparata, Ramulus Uncariae cum Uncis, Caulis Spatholobi, Å pica Prunellae, Semen Cassiae, HR P20180783 T1 Concha Margaritifera Usta, Rhizoma Corydalis i Herba Asari u odnosu na ekscipijente je 40:60 do 65:35, poželjno 55:45 do 65:35.
the genetically modified host cell is not a human cell. The composition of claim 11, the one or more nucleic acids of any one of claims 12-14, or the kit of claim 15, or the genetically modified host cell of claim 16, wherein the DNA-targeting RNA comprises one or more of a modified nucleobase, a modified backbone or non-natural internucleoside linkage, a modified sugar moiety, a Locked Nucleic Acid, or a Peptide Nucleic Acid. 
Pripravak u skladu s patentnim zahtjevom 12, jedna ili više nukleinskih kiselina u skladu s bilo kojim od patentnih zahtjeva 13-15, ili komplet u skladu s patentnim zahtjevom 16, ili genetički modificirana stanica domaćin u skladu s patentnim zahtjevom 17, naznačeni time što RNA koja cilja na DNA sadrži jednu ili više modificiranih nukleobaza, modificiranu okosnicu ili neprirodnu internukleozidnu spojnicu, modificirani šećerni ostatak, zaključanu nukleinsku kiselinu ili peptidnu nukleinsku kiselinu.
However, in order to prevent any possible abuse in the event of comminution and/or pulverisation of the dosage form according to the invention which has nevertheless been achieved by application of extreme force, the dosage forms according to the invention may, in a preferred embodiment, contain further agents which complicate or prevent abuse as auxiliary substances (B). 
Da bi se međutim predusrelo svaku moguću zlouporabu oblika davanja prema izumu, oblici davanja prema izumu u pogodnom izvedbenom obliku mogu kao pomoćne tvari (B) sadržavati daljnja sredstva koja otežavaju, odnosno sprečavaju zlouporabu.
o is (substantially or entirely) free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.1 mM; 
* ne sadrži aminokiseline ili sadrži jednu 1li više aminokiselina u (zajedničkoj) koncentraciji do najviše 0.1 mM: i
Alternatively a preferred dosage is about 0.6 mg or about 0.9 mg per eye per day. One of the preferred administration routes as mentioned above is via the use of eyedrops. 
2. < siRNK za primjenu prema patentnom zahtjevu 1 gdje je siRNK administrirana u dozi od oko 0.6 mg ili oko 0.9 mg po oku po danu. 3.
A compound of formula II according to claim 1: where: 
(a') reakcije spoja prema formuli 4:
A pharmaceutical composition comprising one of the following combinations of compounds: 
Farmaceutska smjesa koja sadrži jednu od sljedećih kombinacija spojeva:
a terpene profile in which myrcene is not the dominant terpene; and a terpene oil content greater than 1.3% by weight; wherein the terpene oil content is the additive content of the terpenes in the terpene profile, wherein the terpene profile consists of terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and myrcene of the plant, and wherein the cannabinoid and terpene contents are measured by GC-FID and calculated based on weight of the extract, wherein extracts comprising a), b), c), and d) are obtainable from a plant comprising the inflorescence of claim 1. 
Cc) - terpenski profil u kojem mircen nije dominantni terpen; i d) = sadržaj terpenskog ulja veći od 1,3%, težinski; gdje je sadržaj terpenskog ulja aditivan sadržaj terpena u terpenskom profilu, gdje se terpenski profil sastoji od terpinolena, o-felandrena, B-ocimena, karena, limonena, y-terpinena, o-pinena, a-terpinena, B-pinena, fenhola, kamfena, o-terpineola, o-humulena, B-kariofilena, linaloola, kariofilen-oksida, te mircena of the biljka, te gdje se sadržaje kanabinoida i terpena mjeri uz pomoć GC-FID, te izračunava na osnovi težine ekstrakta, gdje se ekstrakte koji sadrže a), b), c), te d) može dobiti iz biljke koja sadrži inflorescenciju u skladu s patentnim zahtjevom 1.
The unacylated ghrelin fragments and salt thereof for their use of one of claims 1 or 2, wherein it comprises administering an effective amount of said unacylated ghrelin fragment and salt from about 1 µg kg to about 1 mg/kg. 
Fragmenti neaciliranog grelina i njegove soli za njihovu uporabu prema jednom od zahtjeva 1 ili 2, pri čemu ona sadrži administriranje djelotvorne količine navedenog fragmenta neaciliranog grelina i soli od oko 1 ug kg do oko 1 mg/kg.
at least one wire connected to the distal end portion of the first shaft; 
najmanje jednu poteznu žicu (174) spojenu na distalni krajnji dio (188) izdužene cijevi za vođenje (152);
The idler gear 136 is mounted for rotation on a shaft 138 which may be carried by or fixed to the housing 20. 
Potporni zupčanik (136) se okreće tako što je postavljen na osovinu (138) koja je pričvršćena ili fiksirana na kućište (20).
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
It is another aspect of the present disclosure to provide a nucleic acid molecule encoding at least a binding molecule. 
Molekula nukleinske kiseline za kodiranje molekule za vezanje, naznačena time, da je sukladna bilo kojem od patentnih zahtjeva 1-3.
A molecule according to any one of claims 1 to 3 or a composition according to claim 4 or claim 5 for use in the prevention or treatment of clinical Alzheimer's disease. 
Molekula u skladu s patentnim zahtjevom 4, naznačena time što je namijenjena upotrebi u liječenju ili sprječavanju Alzheimerove bolesti, gdje je navedena Alzheimerova bolest klinički stadij Alzheimerove bolesti.
A compound of Claim 3 wherein R2 is pyridinyl, pyrimidinyl, oxazolyl or thiazolyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen and C1-C4 alkyl. 
je piridinil, pirimidinil, oksazolil ili tiazolil, pri čemu je svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana iz grupe koju čine halogen i C1-C4 alkil.
The process of claim 10, wherein the hydrogenation produces an opioid analgesic composition having an a, B-unsaturated ketone level of less than 25 ppm, less than 15 ppm, less than 10 ppm, or less than 5 ppm. 
Postupak prema zahtjevu 10, naznačen time da hidrogeniranje proizvodi sastav opioidnog analgetika koji ima sadržaj €, B- nezasićenih ketona manji od 25 ppm, manji od 15 ppm, manji od 10 ppm, ili manji od 5 ppm.
A particular compound of the present invention is: 
Datum podnošenja europske prijave patenta:
The process according to claim 1, wherein step (2) of the process is performed in the presence of a transition metal compound, and wherein the transition metal compound is present in an amount of 0.1 mol% or more with respect to compound III. 
HR P20161467 T1 Postupak prema zahtjevu 1, u kome se korak (2) postupka provodi u prisutnosti spoja prijelaznog metala, 1 pri čemu je spoj prijelaznog metala paladijev spoj.
Most preferred is an Acrylate/C10-C30 alkyl acrylate cross polymer of C10-30 alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or one of their simple esters crosslinked within allyl ether of sucrose or an allyl ether of pentaerythritol, available under the trade names of Pemulen TR-1 and Pemulen TR-2 from B.F. Goodrich. 
Najpoželjniji je akrilat/Cio-C29 alkil akrilatni unakrsni polimer C;9.30 alkil akrilata i jednog ili više monomera akrilne kiseline, metakrilne kiseline ili jednog od njihovih jednostavnih estera unakrsno povezanih unutar alil etera saharoze ili alil etera pentaeritritola, dostupan pod trgovačkim nazivima Pemulen TR-1 i Pemulen TR-2 od B.F. Goodrich.
To facilitate isolation of the product of formula (VIII), the reaction mixture preferably comprises an organic solvent in which the byproduct M1-R3 has low solubility. Nonlimiting examples of suitable organic solvents include methylcyclohexane, cyclohexane, heptane, hexane, and toluene. 
Postupak prema patentnom zahtjevu 38, pri čemu reakcijska smjesa u koraku (c) sadrži organsko otapalo u kojem sporedni proizvod M-R> ima nisku otopljivost, izabran iz grupe koju čine metilcikloheksan, cikloheksan, heptan, heksan, toluen i njihove smjese.
A conjugate for use as a medicament, said conjugate comprising an antibody according to any one of claims 22-30 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 vezano za terapijski agens, pri čemu je terapijski agens poželjno toksin, radioizotop, lijek ili citotoksični agens.
A still further aspect of the present invention relates to a device for producing a beverage from a capsule (24), comprising a security sensor which enables the driving activity of the motor from the opened state to the closed state only as long as no obstacle is sensed in a space confined by the two approaching jaw members. 
Još jedan daljnji aspekt predmetnog izuma se odnosi na postupak za proizvodnju napitka iz čahure (24) koji uređaj ima sigurnosni senzor koji omogućava pogonsku aktivnost motora od otvorenog do zatvorenog položaja samo toliko dugo dok se nc osjeti prepreka u prostoru koji je obuhvaćen s dva clementa čeljusti koji se međusobno približavaju.
The method according to claim 22, further comprising converting the crystalline base of Compound I into a salt of Compound I. 
Postupak prema zahtjevu 22, dalje obuhvaća pretvorbu kristalične baze Spoja I u sol Spoja I.
The shoe according to claim 18, characterized in that said sole is provided by direct injection of a material which is liquid or very fluid at the time of said injection. 
Cipela u skladu s patentnim zahtjevom 18, naznačena time, da se navedeni potplat dobiva izravnim ubrizgavanjem materijala koji je u trenutku navedenog ubrizgavanja u tekućem stanju ili vrlo iluidan.
Figure 7 and table 17 show the results of these experiments. 
Rezultati tih pokusa prikazani su na Slici 7 i u Tablici 18.
An antibody of any one of claims 1-7 and/or a conjugate of claim 8 for use in a method of (i) inhibiting growth of a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface, (ii) killing a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface, or (iii) inhibiting metastatic spread of a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1-6 i/ili konjugat prema patentnom zahtjevu 7 za upotrebu u postupku (i) inhibicije rasta stanice raka koja eksprimira CLDNG6 i koja je naznačena vezom CLDNG6 s njezinom staničnom površinom, (ii) ubijanja stanice raka koja eksprimira CLDNG i koja je naznačena vezom CLDNG6 s njezinom staničnom površinom ili (iii) inhibicije metastatskog širenja stanice raka koja eksprimira CLDN6 i koja je naznačena vezom CLDNG6 s njezinom staničnom površinom.
A pharmaceutical composition comprising Compound (I) or a salt of Compound (I) and one or more pharmaceutically acceptable carriers, diluents and excipients for use in the treatment of a disease in the central nervous system, in particular psychosis, such as schizophrenia, characterized in that the pharmaceutical composition comprising Compound (I) is administered semiweekly or weekly in an instant release formulation (IR-formulation), an extended, controlled or a delayed release formulation for oral administration. 
Farmaceutski sastav koji sadrži Spoj (1) ih ili sol Spoja (1) i jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača ili ekscipijensa za uporabu u liječenju bolesti centralnog živčanog sustava, posebno psihoze, poput shizofrenije, naznačen time što se farmaceutski sastav koji sadrži Spoj (I) primjenjuje dvaput tjedno ili jednom tjedno u formulaciji sa trenutnim ispuštanjem (IR-formulacija), u formulaciji sa produženim, kontroliranim ili odgođenim ispuštanjem, za oralnu primjenu.
The method according to claim 23, wherein in order to further strengthen the assembly margin of the membrane, a waterproof reinforcement element, or a waterproof heat-sealing tape, which is elastic and made of synthetic material, is applied directly to the lower edge of the membrane. 
Postupak u skladu s jednim ili više od prethodnih patentnih zahtjeva, naznačen time, da se nepromočivi element za ojačavanje (651), radi dodatnog ojačavanja prepusta za montažu membrane, koja je poželjno elastična 1 izrađena od sintetičkih materijala, postavlja izravno na donji rub membrane.
Anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment binding to adrenomedullin for use in therapy of an acute disease or acute condition of a patient according to any of claims 1 to 10, wherein said antibody or fragment is an antibody or fragment that binds to ADM, wherein the heavy chain comprises the sequences: 
Protutijelo protiv adrenomedđulina (ADM) ili fragment protutijela protiv ADM koji se veže na adrenomedulin, namijenjeni upotrebi u terapiji akutne bolesti ili akutnog stanja kod pacijenta u skladu bilo kojim od patentnih zahtjeva 1 do 10, naznačeni time što su navedeno protutijelo ili fragment protutijelo ili fragment koji se vežu na ADM, gdje teški lanac sadrži sljedove:
The anti-CTLA-4 antibody and 2'-deoxy-2',2'-difluorocytidine monohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 3, wherein the cancer is a solid tumor. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, gdje je navedeni rak solidni tumor.
Achieving a high dose reproducibility with micronised powders is difficult because of their poor flowability and extreme agglomeration tendency. 
Zbog slabe tečljivosti 1 ekstremne sklonosti aglomeriranja teško se postiže visoka ponovljivost odmjeravanja doze mikroniziranih prašaka.
The method of claim 1, wherein the disease is multiple sclerosis. 
Spoj za uporabu prema zahtjevu 11, naznačen time što je bolest multipla skleroza.
A further preferred embodiment of the present invention is represented by those combinations which comprise as component A) a compound of the formula I, wherein Y is and R1 is difluoromethyl; and one component B) as described above. 
Postupak prema zahtjevu 1, naznačen time, da je komponenta A) spoj sa formulom I, pri čemu R, je difluorometil, Y je -CHR-, te R, je izopropil.
represents either a single bond or a double bond; provided that when ---- represents a single bond, U and U', the same or different, independently represent H and W and W, the same or different, are independently selected from the group consisting of OH, -OR, -OCOR, -OCOOR, -OCONRR', a cyclic carbamate such that N10 and C11 are a part of the cycle, -NRCONRR', -OCSNHR, a cyclic thiocarbamate such that N10 and C11 are a part of the cycle, -SH, -SR, -SOR, -SOOR, -SO3, -OSO3, -NRSOOR, -NRR', optionally cyclic amine such that N10 and C11 are a part of the cycle, - NROR', -NRCOR, -N3, a cyano, a halo, a trialkyl or triarylphosphonium; 
predstavlja bilo jednostruku vezu ili dvostruku vezu; uz uvjet da kada predstavlja jednostruku vezu, U i U', isti ili različiti, neovisno predstavljaju H, a W i W', iste ili različite, se neovisno bira iz skupine koju čine OH, -OR, -OCOR, -OCOOR, -OCONRR ', ciklički karbamat u kojem N10 i CII čine dio prstena, -NRCONRR/, -OCS-NHR, ciklički tiokarbamat u kojem N10 i CII čine dio prstena, -SH, -SR, -SOR, -SOOR, -SO;, -OSO;, -NRSOOR, -NRR', izborno ciklički amin u kojem NIO i CII čino dio prstena, -NROR', -NRCOR, -N, cijano, halogen, trialkil ili triarilfosfonij; a kada predstavlja dvostruku vezu, U i U' su odsutni, a W i W' predstavljaju H;
a thermal gas emitting composition (TGEC) being an aqueous solution or suspension comprising at least one compound selected from the group consisting of hydrazine nitrate, 1,1-di C2-6 alkyl hydrazine nitrates and 1,2-di-C2-6 alkyl hydrazine nitrates, such as 1,1-dimethyl hydrazine nitrate or 1,2-dimethyl hydrazine nitrate, guanidine nitrate, formamide nitric acid adduct, acetamide nitric acid adduct, acetonitrile nitric acid adduct, urea nitric acid adduct, ammonium nitrate, potassium nitrate, sodium nitrate, calcium nitrate, mono, di and tri C1-5 alkyl amine nitrates, mono, di and tri C1-5 alkanol amine nitrates, C2-6 alkylene diamine mono and dinitrates and poly C1-5 alkylene polyamine polynitrates; and a reaction initiator stabilizer (RIS) being a liquid solution or suspension and comprising at least one compound selected from the group consisting of: 
sastav koji emitira termalni plin (Thermal gas emitting composition – TGEC) koji je vodena otopina ili suspenzija, što sadrži barem jedan spoj odabran iz skupine koja se sastoji od hidrazin nitrata, 1,1-di C2-6 alkil hidrazin nitrata i 1,2-di-C2-6 alkil hidrazin nitrata, kao što su 1,1-dimetil hidrazin nitrat ili 1,2-dimetil hidrazin nitrat, gvanidin nitrat, adicioni spoj formamid dušična kiselina, adicioni spoj acetamid dušična kiselina, adicioni spoj acetonitril dušična kiselina, adicioni spoj urea dušična kiselina, amonijakov nitrat, kalijev nitrat, natrijev nitrat, kalcijev nitrat, mono, di i tri C1-5 alkil amin nitrati, mono di i tri C1-5 alkanol amin nitrati, C2-6 alkilen diamin mono i dinitrati ipoli C1-5 alkilen poliamin polinitrati; i stabilizator-inicijator reakcije (Reaction initiator stabilizer - RIS), koji je tekuća otopina ili suspenzija i sadrži barem jedan spoj odabran iz skupine koja se sastoji od: